View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088
Open access

A neuroendokrin daganatok kialakulására több öröklődő daganatszindróma hajlamosít, és az ezekben szereplő molekuláris mechanizmusok a daganatok döntő többségét kitevő sporadikus előfordulású daganatokban is kimutathatóak. A multiplex endokrin neoplasia 1-es típusa, a von Hippel–Lindau-szindróma, a neurofibromatosis 1-es típusa és a sclerosis tuberosa a legfontosabb daganatszindrómák, amelyek neuroendokrin daganatra hajlamosítanak. Ezek mindegyike autoszomális domináns öröklésmenetet követ. A főbb érintett molekuláris útvonalak közé tartozik a Ras-MAPK jelátviteli út, a hypoxia indukálta faktor-1α, az mTOR-jelátvitel, amelyek a sporadikus daganatokban is fontos szerepet játszanak és potenciális molekuláris célpontként is szóba jöhetnek a neuroendokrin daganatok kezelésében. Az összefoglaló közlemény az öröklődő daganatszindrómák főbb jellemzőit, molekuláris genetikáját és a sporadikus daganatok kialakulásában szerepet játszó patomechanizmusokat tárgyalja. Orv. Hetil., 2013, 154, 1541–1548.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Igaz, P., Igaz, I., Rácz, K., et al.: Hereditary tumours of the endocrine pancreas. [Az endokrin pancreas öröklődő daganatai.] Orv. Hetil., 2006, 147, 195–200. [Hungarian]

    Rácz K. , 'Hereditary tumours of the endocrine pancreas. [Az endokrin pancreas öröklődő daganatai.] ' (2006 ) 147 Orv. Hetil. : 195 -200.

    • Search Google Scholar
  • Brandi, M. L., Gagel, R. F., Angeli, A., et al.: Consensus. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab., 2001, 86, 5658–5671.

    Angeli A. , 'Consensus. Guidelines for diagnosis and therapy of MEN type 1 and type 2 ' (2001 ) 86 J. Clin. Endocrinol. Metab. : 5658 -5671.

    • Search Google Scholar
  • Thakker, R. V.: Multiple endocrine neoplasia type 1 (MEN1). Best Pract. Res. Clin. Endocrinol. Metab., 2010, 24, 355–370.

    Thakker R. V. , 'Multiple endocrine neoplasia type 1 (MEN1) ' (2010 ) 24 Best Pract. Res. Clin. Endocrinol. Metab. : 355 -370.

    • Search Google Scholar
  • Igaz, P.: MEN1 clinical background. In: Balogh, K., Patócs, A. (eds.) SuperMEN1: Pituitary, parathyroid and pancreas. Landes Bioscience–Spinger, New York, Austin, 2009, 1–15.

    Igaz P. , '', in SuperMEN1: Pituitary, parathyroid and pancreas , (2009 ) -.

  • Wang, Y., Ozawa, A., Zaman, S., et al.: The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Res., 2011, 71, 371–382.

    Zaman S. , 'The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization ' (2011 ) 71 Cancer Res. : 371 -382.

    • Search Google Scholar
  • Tichomirowa, M. A., Daly, A. F., Beckers, A.: Familial pituitary adenomas. J. Intern. Med., 2009, 266, 5–18.

    Beckers A. , 'Familial pituitary adenomas ' (2009 ) 266 J. Intern. Med. : 5 -18.

  • Yao, J. C.: Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract. Res. Clin. Endocrinol. Metab., 2007, 21, 163–172.

    Yao J. C. , 'Molecular targeted therapy for carcinoid and islet-cell carcinoma ' (2007 ) 21 Best Pract. Res. Clin. Endocrinol. Metab. : 163 -172.

    • Search Google Scholar
  • Schmitt, A. M., Schmid, S., Rudolph, T., et al.: VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr. Relat. Cancer, 2009, 16, 1219–1227.

    Rudolph T. , 'VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors ' (2009 ) 16 Endocr. Relat. Cancer : 1219 -1227.

    • Search Google Scholar
  • Charlesworth, M., Verbeke, C. S., Falk, G. A., et al.: Pancreatic lesions in von Hippel–Lindau disease? A systematic review and meta-synthesis of the literature. J. Gastrointest. Surg., 2012, 16, 1422–1428.

    Falk G. A. , 'Pancreatic lesions in von Hippel–Lindau disease? A systematic review and meta-synthesis of the literature ' (2012 ) 16 J. Gastrointest. Surg. : 1422 -1428.

    • Search Google Scholar
  • Zikusoka, M. N., Kidd, M., Eick, G., et al.: The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer, 2005, 104, 2292–2309.

    Eick G. , 'The molecular genetics of gastroenteropancreatic neuroendocrine tumors ' (2005 ) 104 Cancer : 2292 -2309.

    • Search Google Scholar
  • Jimenez, C., Cabanillas, M. E., Santarpia, L., et al.: Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel–Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J. Clin. Endocrinol. Metab., 2009, 94, 386–391.

    Santarpia L. , 'Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel–Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors ' (2009 ) 94 J. Clin. Endocrinol. Metab. : 386 -391.

    • Search Google Scholar
  • Jonasch, E., McCutcheon, I. E., Waguespack, S. G., et al.: Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease. Ann. Oncol., 2011, 22, 2661–2666.

    Waguespack S. G. , 'Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease ' (2011 ) 22 Ann. Oncol. : 2661 -2666.

    • Search Google Scholar
  • Gutmann, D. H., Aylsworth, A., Carey, J. C., et al.: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA, 1997, 278, 51–57.

    Carey J. C. , 'The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2 ' (1997 ) 278 JAMA : 51 -57.

    • Search Google Scholar
  • Basile, U., Cavallaro, G., Polistena, A., et al.: Gastrointestinal and retroperitoneal manifestations of type 1 neurofibromatosis. J. Gastrointest. Surg., 2010, 14, 186–194.

    Polistena A. , 'Gastrointestinal and retroperitoneal manifestations of type 1 neurofibromatosis ' (2010 ) 14 J. Gastrointest. Surg. : 186 -194.

    • Search Google Scholar
  • DeBella, K., Szudek, J., Friedman, J. M.: Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics, 2000, 105, 608–614.

    Friedman J. M. , 'Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children ' (2000 ) 105 Pediatrics : 608 -614.

    • Search Google Scholar
  • Capurso, G., Festa, S., Valente, R., et al.: Molecular pathology and genetics of pancreatic endocrine tumours. J. Mol. Endocrinol., 2012, 49, R37–R50.

    Valente R. , 'Molecular pathology and genetics of pancreatic endocrine tumours ' (2012 ) 49 J. Mol. Endocrinol. : R37 -R50.

    • Search Google Scholar
  • Curatolo, P., Bombardieri, R., Jozwiak, S.: Tuberous sclerosis. Lancet, 2008, 372, 657–668.

    Jozwiak S. , 'Tuberous sclerosis ' (2008 ) 372 Lancet : 657 -668.

  • Dworakowska, D., Grossman, A. B.: Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr. Relat. Cancer, 2009, 16, 45–58.

    Grossman A. B. , 'Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review ' (2009 ) 16 Endocr. Relat. Cancer : 45 -58.

    • Search Google Scholar
  • Duerr, E. M., Mizukami, Y., Ng, A., et al.: Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr. Relat. Cancer, 2008, 15, 243–256.

    Ng A. , 'Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis ' (2008 ) 15 Endocr. Relat. Cancer : 243 -256.

    • Search Google Scholar
  • Moore, P. S., Missiaglia, E., Antonello, D., et al.: Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer, 2001, 32, 177–181.

    Antonello D. , 'Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL ' (2001 ) 32 Genes Chromosomes Cancer : 177 -181.

    • Search Google Scholar
  • Wiedenmann, B., Pavel, M., Kos-Kudla, B.: From targets to treatments: A review of molecular targets in pancreatic neuroendocrine tumors. Neuroendocrinology, 2011, 94, 177–190.

    Kos-Kudla B. , 'From targets to treatments: A review of molecular targets in pancreatic neuroendocrine tumors ' (2011 ) 94 Neuroendocrinology : 177 -190.

    • Search Google Scholar
  • Cingarlini, S., Bonomi, M., Corbo, V., et al.: Profiling mTOR pathway in neuroendocrine tumors. Target. Oncol., 2012, 7, 183–188.

    Corbo V. , 'Profiling mTOR pathway in neuroendocrine tumors ' (2012 ) 7 Target. Oncol. : 183 -188.

    • Search Google Scholar
  • Yao, J. C., Shah, M. H., Ito, T., et al.: Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364, 514–523.

    Ito T. , 'Everolimus for advanced pancreatic neuroendocrine tumors ' (2011 ) 364 N. Engl. J. Med. : 514 -523.

    • Search Google Scholar
  • Raymond, E., Dahan, L., Raoul, J. L., et al.: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364, 501–513.

    Raoul J. L. , 'Sunitinib malate for the treatment of pancreatic neuroendocrine tumors ' (2011 ) 364 N. Engl. J. Med. : 501 -513.

    • Search Google Scholar
  • Karpathakis, A., Dibra, H., Thirlwell, C.: Neuroendocrine tumours: Cracking the epigenetic code. Endocr. Relat. Cancer, 2013, 20, R65–R82.

    Thirlwell C. , 'Neuroendocrine tumours: Cracking the epigenetic code ' (2013 ) 20 Endocr. Relat. Cancer : R65 -R82.

    • Search Google Scholar
  • Hanahan, D., Weinberg, R. A.: Hallmarks of cancer: The next generation. Cell, 2011, 144, 646–674.

    Weinberg R. A. , 'Hallmarks of cancer: The next generation ' (2011 ) 144 Cell : 646 -674.

  • Arnold, C. N., Nagasaka, T., Goel, A., et al.: Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. Int. J. Cancer, 2008, 123, 1556–1564.

    Goel A. , 'Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors ' (2008 ) 123 Int. J. Cancer : 1556 -1564.

    • Search Google Scholar
  • Trask, B. J.: Human cytogenetics: 46 chromosomes, 46 years and counting. Nat. Rev. Genet., 2002, 3, 769–778.

    Trask B. J. , 'Human cytogenetics: 46 chromosomes, 46 years and counting ' (2002 ) 3 Nat. Rev. Genet. : 769 -778.

    • Search Google Scholar
  • Robertson, K. D.: DNA methylation and human disease. Nat. Rev. Genet., 2005, 6, 597–610.

    Robertson K. D. , 'DNA methylation and human disease ' (2005 ) 6 Nat. Rev. Genet. : 597 -610.

  • Tömböl, Z., Szabó, P., Rácz, K., et al.: Relevance of microRNAs in neoplastic diseases. [A mikro-RNS-ek jelentősége daganatos betegségekben.] Orv. Hetil., 2007, 148, 1135–1141. [Hungarian]

    Rácz K. , 'Relevance of microRNAs in neoplastic diseases. [A mikro-RNS-ek jelentősége daganatos betegségekben.] ' (2007 ) 148 Orv. Hetil. : 1135 -1141.

    • Search Google Scholar
  • Yokoyama, A., Wang, Z., Wysocka, J., et al.: Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol., 2004, 24, 5639–5649.

    Wysocka J. , 'Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression ' (2004 ) 24 Mol. Cell. Biol. : 5639 -5649.

    • Search Google Scholar
  • Arnold, C. N., Sosnowski, A., Schmitt-Gräff, A., et al.: Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. Int. J. Cancer, 2007, 120, 2157–2164.

    Schmitt-Gräff A. , 'Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system ' (2007 ) 120 Int. J. Cancer : 2157 -2164.

    • Search Google Scholar
  • Kidd, M., Eick, G., Shapiro, M. D., et al.: Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer, 2005, 103, 229–236.

    Shapiro M. D. , 'Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors ' (2005 ) 103 Cancer : 229 -236.

    • Search Google Scholar
  • Nagy, Z., Szabó, D. R., Zsippai, A., et al.: Relevance of long non-coding RNAs in tumour biology. [A hosszú nem kódoló RNS-ek jelentősége a daganatbiológiában.] Orv. Hetil., 2012, 153, 1494–1501. [Hungarian]

    Zsippai A. , 'Relevance of long non-coding RNAs in tumour biology. [A hosszú nem kódoló RNS-ek jelentősége a daganatbiológiában.] ' (2012 ) 153 Orv. Hetil. : 1494 -1501.

    • Search Google Scholar
  • Veronese, A., Lupini, L., Consiglio, J., et al.: Oncogenic role of miR-483–3p at the IGF2/483 locus. Cancer Res., 2010, 70, 3140–3149.

    Consiglio J. , 'Oncogenic role of miR-483–3p at the IGF2/483 locus ' (2010 ) 70 Cancer Res. : 3140 -3149.

    • Search Google Scholar
  • Roldo, C., Missiaglia, E., Hagan, J. P., et al.: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol., 2006, 24, 4677–4684.

    Hagan J. P. , 'MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior ' (2006 ) 24 J. Clin. Oncol. : 4677 -4684.

    • Search Google Scholar
  • Larsson, C.: Epigenetic aspects on therapy development for gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology, 2013, 97, 19–25.

    Larsson C. , 'Epigenetic aspects on therapy development for gastroenteropancreatic neuroendocrine tumors ' (2013 ) 97 Neuroendocrinology : 19 -25.

    • Search Google Scholar